Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | WDR5 | P61964 | 3/20 | 0.40 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.40 |
| ▸ | ATP4A | P20648 | 2/20 | 0.33 |
| ▸ | ATP4B | P51164 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | BRS3 | P32247 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.30 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azeloprazole SCHEMBL4333430 | 1.00 | KMT2A (0.40) | KMT2AWDR5SARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL31312701 | 1.00 | KMT2A (0.40) | KMT2AWDR5SARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL4333414 | 1.00 | KMT2A (0.40) | KMT2AWDR5SARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL4492343 | 0.99 | WDR5 (0.40) | KMT2AWDR5SARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL4336045 | 0.99 | WDR5 (0.40) | KMT2AWDR5SARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL4338561 | 0.99 | WDR5 (0.40) | KMT2AWDR5SARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL711094 | 0.99 | WDR5 (0.40) | KMT2AWDR5SARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL4338563 | 0.99 | WDR5 (0.40) | KMT2AWDR5SARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL711093 | 0.99 | WDR5 (0.40) | KMT2AWDR5SARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL4336050 | 0.99 | WDR5 (0.40) | KMT2AWDR5SARM1ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1870409-B1 | BENZIMIDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-05-12 | — | — | EP | claimed |
| US-20090274756-A1 | Stabilized composition | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-05 | — | — | US | claimed |
| US-20090182149-A1 | SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-16 | — | — | US | claimed |
| EP-2077265-A1 | SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2009-07-08 | — | — | EP | claimed |
| US-7425634-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | claimed |
| US-20080145421-A1 | A layer of a benzamidazole-proton pump inhibitor and ethyl celluose is coated on an inert or basic material core material; an exterior layer of enteric polymer to prevent the dissolution of the drug in the stomach but in the intestines; storage stability; time-release agents; gastrointestinal disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-06-19 | — | — | US | claimed |
| EP-1875911-A1 | STABILIZED COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2008-01-09 | — | — | EP | claimed |
| EP-1870409-A1 | BENZIMIDAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-12-26 | — | — | EP | claimed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | claimed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | claimed |
| US-9040564-B2 | Stabilized composition | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040564-B2 | Stabilized composition | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040564-B2 | Stabilized composition | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20130189360-A1 | COMPRESSED COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-07-25 | — | — | US | disclosed |
| EP-2601936-A1 | COMPRESSED COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-6974810-B2 | cannabinoid (cb1); treating disorders involving cannabinoid neurotransmission | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-12-13 | — | — | US | disclosed |
| US-20040106800-A1 | 4,5-Dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity | ABBVIE B.V. (NL) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182149-A1 | SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF | BRI3BP, SNRK, SRI | KMT2A 500/4885WDR5 1543/4885SARM1 3558/4885 |
| US-20080145421-A1 | A layer of a benzamidazole-proton pump inhibitor and ethyl celluose is coated on an inert or basic material core material; an exterior layer of enteric polymer to prevent the dissolution of the drug in the stomach but in the intestines; storage stability; time-release agents; gastrointestinal disorders | SI, CEL, PGA5 | KMT2A 3022/4885WDR5 3817/4885SARM1 4854/4885 |
| US-20090274756-A1 | Stabilized composition | SI, PGA5, CEL | KMT2A 4419/4885WDR5 3071/4885SARM1 4820/4885 |
| US-20070010542-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | KMT2A 4213/4885WDR5 793/4885SARM1 4535/4885 |
| US-20070015782-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | KMT2A 4213/4885WDR5 793/4885SARM1 4535/4885 |
| US-20040106800-A1 | 4,5-Dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity | CNR1, CNR2, FAAH | KMT2A 2975/4885WDR5 2436/4885SARM1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.